References
- Mease P, Helliwell P, Hjuler K, et al. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis. 2021;80(2):185–193.
- AbbVie News Center. AbbVie submits regulatory applications for SKYRIZI® (risankizumab) in psoriatic arthritis to FDA and EMA. [cited 2021 Aug 26]. Available from: https://news.abbvie.com/news/press-releases/abbvie-submits-regulatory-applications-for-skyrizi-risankizumab-in-psoriatic-arthritis-to-fda-and-ema.htm
- van der Heijde D, Gladman DD, Kavanaugh A, et al. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Res Ther. 2020;22(1):1–9.
- Gottlieb A, Merola J. Psoriatic arthritis for dermatologists. J Dermatolog Treat. 2020;31(7):662–679.